PT - JOURNAL ARTICLE AU - Danter, WR TI - Age-Dependent Effects of UV Exposure and Xeroderma Pigmentosum Group A on DNA Damage, Repair Mechanisms, Genomic Instability, Cancer Risk, and Neurological Disorders AID - 10.1101/2024.07.22.24310800 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.22.24310800 4099 - http://medrxiv.org/content/early/2024/07/22/2024.07.22.24310800.short 4100 - http://medrxiv.org/content/early/2024/07/22/2024.07.22.24310800.full AB - Background Xeroderma pigmentosum, complementation group A (XPA), is a rare genetic disorder characterized by marked sensitivity to ultraviolet (UV) radiation, leading to increased risks of skin cancer, accelerated aging, and significant neurologic disorders. XPA prominently impacts DNA repair mechanisms, specifically nucleotide excision repair (NER), which is crucial for correcting UV-induced DNA damage.Methods This study utilized an advanced aiHumanoids platform to simulate the disease progression in individuals with XPA from birth to age 20 years. The virtual longitudinal study assessed the impacts of moderate and severe XPA under various UV exposure scenarios. The research included 25 age-matched wild-type controls to elucidate the comparative effects of XPA on DNA damage, genomic instability, cancer risk, and neurological outcomes.Results Using Wilcoxon sign rank p values and Cliff’s delta estimates of true effect size, the aiHumanoid simulations revealed significant differences in DNA repair efficiency between XPA affected and control groups, with pronounced deficits in XPA cohorts under UV exposure. Genomic instability and skin cancer risks were consistently elevated across all XPA simulations, particularly under UV stress. Neurological assessments indicated greater susceptibility to disorders in younger XPA subjects, with effects moderating somewhat with age.Conclusion The aiHumanoid platform provided novel insights into the progression of XPA, highlighting the severe impact of UV exposure on individuals with this condition. These findings advocate for early intervention strategies and underscore the necessity for rigorous protective measures against UV radiation, especially in younger populations. This research contributes to our further understanding of XPA, potentially guiding future therapeutic developments including early stage virtual drug trials and preventive approaches personalized to individual risk profiles.Competing Interest StatementThe author is the unpaid founder and Chief Science Officer of 123Genetix Inc. a private AI based research organization focusing on rare diseasesFunding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Draft virtual patient profiles were generated by GPT4 (December, 2023 version) and then reviewed and edited by an experienced physician.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the author.